Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 Pembrolizumab (anti-PD-1)
For research use only. Not for use in humans.

Pembrolizumab (anti-PD-1)

Synonyms: MK-3475, lambrolizumab

Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

Pembrolizumab (anti-PD-1) Chemical Structure

Click to purchase the isotype control of Pembrolizumab (anti-PD-1)

77 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.78 mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Features
Human IgG4
Targets/IC50/Ki
PD-1
(Cell-free assay)
In vitro

The level of LDH and apoptosis are significantly higher in those treated with dexamethasone plus PD1 inhibitor pembrolizumab than other groups.
Cell Research

Cancer cells were incubated with dexamethasone for 48 h followed by co-cultured with PBMCs with effector/target ratio of 10:1 and the addition of PD1 inhibitor (pembrolizumab; 5 μg/mL) for another 48 h. LDH level was detected.
In vivo

Pembrolizumab and dexamethasone synergistically suppress tumor growth of pancreatic cancer in vivo.
Animal Research

Animal Models: Immune reconstituted NOD/SCID mice model
Dosages: 5 mg/kg
Administration: i.v.
Reference: [1]
 
References

Product Details

CAS No. 1374853-91-4
Isotype Human IgG4
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04198766 RECRUITING Drug: INBRX-106 - Hexavalent OX40 agonist antibody|Drug: pem Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer Inhibrx Biosciences, Inc 2019-12-10 PHASE1; PHASE2
NCT07178730 NOT_YET_RECRUITING Drug: Sacituzumab govitecan|Drug: Pembrolizumab 25 mg/1 ML I Breast Cancer; Triple-negative Breast Cancer Women's Cancer Study Group GmbH 2026-08-30 PHASE3
NCT07383441 RECRUITING Drug: Axitinib|Drug: Cabozantinib|Drug: Clostridium butyricu Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 SWOG Cancer Research Network 2026-06-05 PHASE3
NCT06606730 RECRUITING Drug: Pembrolizumab Breast Cancers; Triple Negative Breast Cancer (TNBC) UNICANCER 2025-07-23 PHASE3
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT06952504 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Docetaxel|Drug: Cis Endometrial Cancer Merck Sharp & Dohme LLC 2025-05-22 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.